CN114026083B - 酪氨酸激酶的杂环抑制剂 - Google Patents

酪氨酸激酶的杂环抑制剂 Download PDF

Info

Publication number
CN114026083B
CN114026083B CN202080045535.4A CN202080045535A CN114026083B CN 114026083 B CN114026083 B CN 114026083B CN 202080045535 A CN202080045535 A CN 202080045535A CN 114026083 B CN114026083 B CN 114026083B
Authority
CN
China
Prior art keywords
compound
egfr
group
her2
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045535.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114026083A (zh
Inventor
J·海马赫
J·罗比肖
M·尼尔松
P·琼斯
J·克罗斯
J·泰鲁夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Priority to CN202410871766.0A priority Critical patent/CN118852118A/zh
Publication of CN114026083A publication Critical patent/CN114026083A/zh
Application granted granted Critical
Publication of CN114026083B publication Critical patent/CN114026083B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080045535.4A 2019-04-25 2020-04-24 酪氨酸激酶的杂环抑制剂 Active CN114026083B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410871766.0A CN118852118A (zh) 2019-04-25 2020-04-24 抑制酪氨酸激酶活性的化合物和包括其的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838696P 2019-04-25 2019-04-25
US62/838,696 2019-04-25
PCT/US2020/029849 WO2020219904A1 (en) 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410871766.0A Division CN118852118A (zh) 2019-04-25 2020-04-24 抑制酪氨酸激酶活性的化合物和包括其的药物组合物

Publications (2)

Publication Number Publication Date
CN114026083A CN114026083A (zh) 2022-02-08
CN114026083B true CN114026083B (zh) 2024-07-09

Family

ID=72941423

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080045535.4A Active CN114026083B (zh) 2019-04-25 2020-04-24 酪氨酸激酶的杂环抑制剂
CN202410871766.0A Pending CN118852118A (zh) 2019-04-25 2020-04-24 抑制酪氨酸激酶活性的化合物和包括其的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410871766.0A Pending CN118852118A (zh) 2019-04-25 2020-04-24 抑制酪氨酸激酶活性的化合物和包括其的药物组合物

Country Status (7)

Country Link
US (1) US11365189B2 (enExample)
EP (1) EP3962908B1 (enExample)
JP (1) JP7601788B2 (enExample)
CN (2) CN114026083B (enExample)
AU (1) AU2020261423B2 (enExample)
CA (1) CA3137901A1 (enExample)
WO (1) WO2020219904A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
KR20220147021A (ko) * 2021-04-22 2022-11-02 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266425A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 3-cyano-quinoline derivatives and uses thereof
WO2023028054A1 (en) * 2021-08-24 2023-03-02 Arthrosi Therapeutics, Inc. Quinazoline compounds for treatment of disease
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536114A (en) 2002-03-30 2007-11-30 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
HK1244278B (zh) * 2015-03-20 2020-04-17 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
WO2018036539A1 (zh) * 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry;Eunyoung Kim等;Rapid Commun. Mass Spectrom.;第27卷;第1183-1195页 *

Also Published As

Publication number Publication date
CN118852118A (zh) 2024-10-29
AU2020261423B2 (en) 2026-01-29
CN114026083A (zh) 2022-02-08
EP3962908A1 (en) 2022-03-09
JP7601788B2 (ja) 2024-12-17
EP3962908B1 (en) 2026-08-12
CA3137901A1 (en) 2020-10-29
US11365189B2 (en) 2022-06-21
WO2020219904A1 (en) 2020-10-29
EP3962908A4 (en) 2022-10-26
US20200354343A1 (en) 2020-11-12
JP2022529518A (ja) 2022-06-22
AU2020261423A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7601788B2 (ja) チロシンキナーゼの複素環式阻害剤
US12186324B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US11713313B2 (en) GLS1 inhibitors for treating disease
ES2788449T3 (es) Inhibidores de GLS1 para tratar enfermedades
CN107635404B (zh) 用于治疗疾病的mct4抑制剂
CN107278202A (zh) 用于治疗炎症和癌症的杂环itk抑制剂
JP2017503815A (ja) がんまたは炎症性疾患を処置するための置換されたピロロピリジンおよびピロロピラジン
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
CN116348112A (zh) 转录激活蛋白的咪唑并哌嗪抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant